Ph 2 Elacestrant in ER Positive Uterine Sarcomas

Summary

This study is to evaluate the efficacy and safety of elacestrant, in participants with advanced estrogen receptor (ER)-positive uterine sarcomas. The name of the study drug involved in this research study is: -Elacestrant (a type of selective estrogen receptor degrader)

Timeline

Start

2026-03-25

Primary completion

2027-07

Completion

2028-04

Drugs

Indications